Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why North American medical cannabis can’t compete globally

Michael Sassano
Meds
February 5, 2023
17 Shares
Share
Tweet
Share

The United States and Canada started a movement that began as medical cannabis and quickly exploded into adult-use cannabis markets. However, the North American operators failed to properly regulate the processes from growing to manufacturing to compete in a global pharmaceutical-level market. Europe has taken the lead as the heavy-weight producer of truly medical-grade pharmaceutical cannabis flowers and products. Notably, many operators in the U.S. and Canada claim to produce medical-grade products, but the structural reality is impossible.

API registration in North America vs. the EU

You must respect requirements when considering registering a medical-grade active pharmaceutical ingredient (API).

Consider cannabis flower cultivation: Although many states and Canada have regulations on how you can grow and what you can use to grow, the pharmaceutical API market is much stricter and requires certification of how you grow and dry. You must grow in line with strict good agricultural and collection processes (GACP) and dry conforming to pharmaceutical good manufacturing processes (GMP) requirements.

Companies that follow European Union-GMP pharmaceutical standards are the gold standard for global medicinal products. The process is regulated, and the reporting and conditions are essential. For example, each new cannabis flower genetic must undergo stability testing to register the API’s shelf life.

International GDP and GLP standards require careful, controlled protocols.

Once you have registered your flower API and the appropriate regulatory agency has accepted the dossier, distribution or further processing adheres to good distribution practices (GDP), and manufacturing follows pharmaceutical GMP. These guidelines and processes have specific requirements for what you are making. Cannabis is a controlled narcotic and requires additional security and properly registered transportation groups to handle and protect the distribution of a controlled substance. GDP and GMP also regulate the cleanliness and air temperatures in the products’ processing or storage rooms. GMP even regulates the airflow inside processing rooms, equipment specifications, cleaning protocols and a litany of requirements for creating products consistently by following protocols and addressing deviations in a controlled fashion.

Good laboratory practices (GLP) are also a large part of product and medicine registrations. Self-governing labs and reporting your lab results at various steps in your processes is crucial to making consistent medicinal products. From the flower to the extraction to distillation and through to formulation and primary packaging, the lab will collect samples to verify conformity. And above the lab is a quality assurance (QA) team monitoring the results, paperwork, and processes by the production team. In simplified flow, the production teams work to make products and send samples throughout the process to the lab for verification, and the QA team watches that procedures are adhered to, and results are in line. The QA team addresses deviations and regulators’ inquiries, all while working to produce consistent medical products registered with regulators.

The impossibility of pharmaceutical cannabis in North America

To a large extent, the adult-use markets of the U.S. are unregulated due to non-federal recognition; otherwise, their governing body would be the Food and Drug Administration (FDA). However, the general rules are not even novel foods GMP and resemble restaurant rules modified with semi-medical requirements like standard operating procedures (SOPs) and independent lab verifications because these are state-regulated entities.

These regulations differ significantly from the strict pharmaceutical GMP standards and the non-standardized global medicinal manufacturing level. Additionally, the buildings’ physical modifications, air handling units, and regulatory requirement updates would make it impossible for almost every facility in the U.S. or Canada to conform to international medicinal standards.

To clarify, it’s unlikely international markets will ever accept U.S. products due to the product manufacturing requirements Europe has adopted.

European operators are poised to lead the global pharmaceutical cannabis market.

In comparison, Europe has strictly adopted the proper medical and pharmaceutical standards for cannabis product growing, drying, manufacturing and distribution. Furthermore, when Europe transforms to an over-the-counter (OTC) model that resembles the adult-use markets of North America, the standard of medical-grade products will enable mainstream distributors and sales outlets like pharmacies to accept the higher standards of products easily.

The global manufacturing and distribution of cannabis require standards to which only novel foods and pharmaceutical GMP products can conform. Additionally, due to cannabis’ scheduling as a psychotropic narcotic, the global rules governing bodies require the trade of pharmaceutical-grade GMP medicines.

These registered APIs and finished market-authorized drugs have the highest quality standards for consumer sale around the globe and can be sold as pharmaceuticals or OTC products that do not require a regular prescription as most drugs do.

As early markets like the U.S. fix cannabis’ federal legal status, they will have to grapple with regulations that could be minimal and follow novel foods GMP or possibly maximal, unachievable pharmaceutical GMP standards. Either way, producers must meet some criteria for consumers’ safety and the products’ uniformity.

Michael Sassano is a health care executive.

Prev

The dark side of medicine: How the profession can become an emotionally and psychologically manipulative relationship

February 5, 2023 Kevin 5
…
Next

Transcription troubles: the hilarious and alarming consequences of speech recognition in medicine

February 5, 2023 Kevin 1
…

Tagged as: Medications

Post navigation

< Previous Post
The dark side of medicine: How the profession can become an emotionally and psychologically manipulative relationship
Next Post >
Transcription troubles: the hilarious and alarming consequences of speech recognition in medicine

Related Posts

  • Digital advances in the medical aid in dying movement

    Jennifer Lynn
  • Clearing the misinformation surrounding medical cannabis

    Samoon Ahmad, MD and Kevin Hill, MD
  • How medical societies can save American medicine

    Steve Levine
  • Supporting anti-racist American medical students: What residency programs can do

    Daniel Skinner, PhD
  • How the COVID-19 pandemic highlights the need for social media training in medical education 

    Oscar Chen, Sera Choi, and Clara Seong
  • End medical school grades

    Adam Lieber

More in Meds

  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Timely treatment decisions: the promise of surrogate markers

    Layla Parast, PhD
  • Most Popular

  • Past Week

    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • Lifestyle change: the forgotten solution in health care

      Tyler Petersen | Conditions
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
  • Recent Posts

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • How medical student loan forgiveness can advance health equity [PODCAST]

      The Podcast by KevinMD | Podcast
    • The rise of generative AI in health care: Here’s what you need to know

      Anil Saldanha | Tech
    • Finding peace through surrender: a personal exploration

      Dympna Weil, MD | Physician
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Unlocking the secret to successful weight loss: Curiosity is the key

      Franchell Hamilton, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Heart Failure's Obesity Paradox Falls Apart on Further Inspection
  • Nobody Wants This Job. Should Physicians Stick Around?
  • Early Postpartum IUD Placement Yields Low Complete Expulsion Rate
  • Hydrocortisone Reduced Mortality in Patients With Severe Pneumonia
  • Obesity Tied to Density of Food Stores Carrying Less Healthy Options, Report Finds

Meeting Coverage

  • Trial of Novel TYK2 Inhibitor Hits Its Endpoint in Plaque Psoriasis
  • Durable Vitiligo Responses With Topical Ruxolitinib
  • High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor
  • Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor
  • New Approaches in the Bladder-Sparing Paradigm
  • Most Popular

  • Past Week

    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • Lifestyle change: the forgotten solution in health care

      Tyler Petersen | Conditions
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
  • Recent Posts

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • How medical student loan forgiveness can advance health equity [PODCAST]

      The Podcast by KevinMD | Podcast
    • The rise of generative AI in health care: Here’s what you need to know

      Anil Saldanha | Tech
    • Finding peace through surrender: a personal exploration

      Dympna Weil, MD | Physician
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Unlocking the secret to successful weight loss: Curiosity is the key

      Franchell Hamilton, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why North American medical cannabis can’t compete globally
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...